When you get a Covid Vaccine you’re being injected with a concentrated Covid Virus directly into your muscle that goes directly into your bloodstream. It’s a direct hit; unlike the air exposure from somebody’s cough or sneeze.
Supercharge it, or more accurately weaponize it, and your body’s immune system responds in kind, meaning it creates a supercharged response that beats you up, burning you like acid, from the inside out. That’s the result like it or not.
The scientists knew this and did it anyway knowing that many people would suffer long term or die – mainly targeting the elderly – a burden on all societies as most think but won’t say. Pfizer committed a holocaust against old people while telling the young people not to take it, because it could sterilize them.
A Supercharged Hit Elicits A Supercharged Response equals death to the cells and in many instances death to the organism. This means that this pfizer #4 booster was designed to kill – organs and people – old people.
Albert Bourla CEO of pfizer pharmaceuticals biotech should be arrested for mass murder with intent to do harm. Many CEOs were given huge payouts from their respective pharmaceutical/biotech companies:
√ Pfizer (NYSE:PFE) Chief Executive and Chairman Albert Bourla will likely become one of the top-earning pharma CEOs for 2022 after the pharma giant took his total compensation to $33.0M handing him a ~36% pay hike for last year.
√ Meanwhile, Johnson & Johnson (JNJ), whose former helmsman Alex Gorsky was the highest-paid pharma CEO in 2021, rewarded its new CEO Joaquin Duato, with a $13.1M package, indicating a ~51% decline in the company’s top executive pay.
√ Gorsky relinquished his CEO role in 2022 after a decade-long tenure as its chairman and CEO, while Bourla, 61, is now serving in his fourth year in the dual leadership position.
√ In 2021, Bourla earned $24.4M, after a ~16% rise from the prior year as the company’s top line jumped ~95% YoY thanks to its blockbuster COVID-19 shot which accounted for over 45% of the top line.
√ However, Pfizer’s (PFE) explosive growth sputtered, and its share price fell as the pandemic subsided. The company revenue reached $10.3B in 2022, which implies a ~23% YoY rise, but still indicates more than double that in 2020.
√ After a ~59% climb in 2021, its share price tumbled ~13%, underperforming its mega-cap pharma rivals, as indicated in this graph.
√ Bourla’s 2022 pay also demonstrates a ~42% rise in his equity-based compensation and a ~4% decline in his non-equity-based incentives, which stand at $18.8M and $7.7M, respectively, according to Pfizer’s latest proxy statement.
√ Meanwhile, Stéphane Bancel, CEO of rival COVID vaccine maker Moderna (MRNA), earned $19.4M in 2022 after the Massachusetts-based biotech raised his total compensation by ~7%.
√ Having recorded $18.5B in revenue for 2021, Moderna’s (MRNA) top line reached $19.3B last year, indicating a ~4% YoY rise while its share price plummeted ~29%, following a ~141% jump in the prior year.
√ Pfizer (PFE) says that the company’s executive compensation implies a median of compensation data from its big pharma peers and a group of non-pharmaceutical companies of similar size and complexity.
√ The pharma peers it has considered include AbbVie (ABBV) and Eli Lilly (LLY), where top management earned $26.3M and $21.4M for 2022, indicating a ~10% rise and ~1% decline in their pay from the prior year, respectively.